Sandoz launches Zarxio biosimilar
Rob Marmion / Shutterstock.com
The US Court of Appeals for the Federal Circuit’s decision in Amgen v Sandoz is what the biosimilar industry would have been hoping for but clarity is lacking in several areas, lawyers have told LSIPR.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Sandoz, Amgen, Zarxio, Neupogen, biosimilar, BPCIA, patent dance